News Related to Humira

Related coverage linked through entity extraction aliases.

Alvotech Reports Positive Clinical Trial Results for AVT80 Biosimilar to Entyvio

Feb 14, 2026

Alvotech announced successful clinical trial results for AVT80, a biosimilar to Takeda's Entyvio, meeting all primary endpoints. The company targets a $6.4 billion market opportunity with regulatory submissions planned.

AbbVie Projects Strong 2026 Growth as Skyrizi and Rinvoq Replace Humira

Feb 13, 2026

AbbVie projects 43-45% earnings growth in 2026 as newer immunology drugs Skyrizi and Rinvoq offset declining Humira sales, while maintaining its 54-year dividend increase streak as a Dividend King.